Hi Trudi

Thank you for your email regarding the research that was used to compare Enlafax with other brands.

This email is to acknowledge that your request for information will be treated as such under the Official Information Act (1982). Your request is currently being worked on and we will have a reply to you as soon as possible and no later than the due date of 7 June 2018.

Kind regards
Katie
PHARMAC

-----Original Message-----
From: Trudi Webber [mailto:[FOI #7784 email]]
Sent: Tuesday, May 8, 2018 9:09 PM
To: Web Enquiry <[email address]>
Subject: [SPAM]? Official Information request - Who did the research that was used to compare Enlafax with other brands?

Dear Pharmaceutical Management Agency,

I have read the information provided by Medsafe quoting all the research facts and figures regarding Enlafax, however it does not clearly state who did the research. Could you please tell me who and where the research was done? Was it research that the company selling the drug did or was it confirmed by independent researchers. This question should be answerable without breaking any confidence as it is not requesting how the product was made but how the research was conducted.

Yours faithfully,

Trudi Webber

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #7784 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

**********************************************************************
This email and any files transmitted with it are confidential and
intended solely for the use of the individual or entity to whom they
are addressed. If you have received this email in error please notify
the system manager.

This footnote also confirms that this email message has been swept by
MIMEsweeper for the presence of computer viruses.

www.clearswift.com
**********************************************************************

hide quoted sections

Hi Trudi

 

Please find attached PHARMAC’s respond to your recent OIA request.

 

Kind regards

Katie

PHARMAC

**********************************************************************

This email and any files transmitted with it are confidential and

intended solely for the use of the individual or entity to whom they

are addressed. If you have received this email in error please notify

the system manager.

This footnote also confirms that this email message has been swept by

MIMEsweeper for the presence of computer viruses.

www.clearswift.com

**********************************************************************

hide quoted sections

Dear Ms Webber

Thank you for your request for official information, received by the
Ministry of Health on 16 May 2018. The Ministry's reference number for
your request is: H201803736.

You requested:

"Could you please tell me who and where the research was done? Was it
research that the company selling the drug did or was it confirmed by
independent researchers. This question should be answerable without
breaking any confidence as it is not requesting how the product was made
but how the research was conducted."

Your request has been logged and you can expect a reply no later than 14
June 2018 as required under the Official Information Act 1982.

Please note that a working day is defined in the Act as ‘any day of the
week other than a Saturday, Sunday, Good Friday, Easter Monday, Anzac Day,
Labour Day, the Sovereigns birthday, Waitangi Day and a day in the period
commencing 25 December in any year and ending 15 January in the following
year.

If a large amount of information has been requested or if the Ministry
needs to consult in order to make a decision, we may need to extend this
date (this is provided for in section 15A of the Act).  We will advise you
if such an extension is necessary.

Yours sincerely,

Maima Koro
Advisor

[email address]
Ministerial Services  l  Government Services  l  Office of the Director
General

[1]http://www.health.govt.nz

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. http://www.health.govt.nz/

hide quoted sections

Dear Ms Webber,

I refer to your official information request received by the Ministry of
Health on 16 May 2018 which was transferred from PHARMAC. To ensure the
Ministry responds to your request appropriately, can you please clarify
whether you are referring to information to support the registration of
Enlafax or the data relating to adverse event reporting.

It will be helpful if you could please provide the specific quote from
Medsafe you are refering to.

Kind regards
Maima
Ministerial Services (OIA)
[email address]  

Government Services
Office of the Director-General
Ministry of Health
[1]www.health.govt.nz
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. file:///tmp/www.health.govt.nz

hide quoted sections

Dear Ms Webber,

Kindly note the Ministry is awaiting your clarification please on your
request.

Kind regards
Maima
Ministerial Services (OIA)
[email address]  

Government Services
Office of the Director-General
Ministry of Health
[1]www.health.govt.nz

From:        OIA Requests/MOH
To:        [FOI #7784 email],
Cc:        OIA Requests/MOH@MOH
Date:        18/05/2018 04:19 p.m.
Subject:        Clarification of your request: H201803736
Sent by:        Maima Koro

--------------------------------------------------------------------------

Dear Ms Webber,

I refer to your official information request received by the Ministry of
Health on 16 May 2018 which was transferred from PHARMAC. To ensure the
Ministry responds to your request appropriately, can you please clarify
whether you are referring to information to support the registration of
Enlafax or the data relating to adverse event reporting.

It will be helpful if you could please provide the specific quote from
Medsafe you are refering to.

Kind regards
Maima
Ministerial Services (OIA)
[email address]  

Government Services
Office of the Director-General
Ministry of Health
[2]www.health.govt.nz

****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************

--------------------------------------------------------------------------

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. file:///tmp/www.health.govt.nz
2. file:///tmp/www.health.govt.nz

hide quoted sections